Boehringer Ingelheim Transforms Safety Reporting with AI-Powered Automation
Boehringer Ingelheim is leveraging generative AI to achieve 90% data accuracy and increased efficiency in its global pharmacovigilance processes, marking a significant step in digital transformation.
Boston, July 8, 2025 – In a move signaling the growing adoption of artificial intelligence in the pharmaceutical industry, Boehringer Ingelheim has implemented LifeSphere® NavaX™, an AI-powered solution developed by ArisGlobal, to streamline its global safety processes. The implementation has yielded a substantial increase in automation and efficiency, particularly in the processing of individual case safety reports (ICSRs).
As part of a broader digital transformation strategy, Boehringer Ingelheim is now utilizing NavaX-supported advanced intake to manage security reports. The application of generative AI (GenAI) and dynamic data extraction technologies is delivering tangible results. Within weeks of deployment, the system achieved an average data extraction accuracy of 90%, significantly reducing manual effort while maintaining rigorous quality control and accelerating timelines.
The successful integration of NavaX represents a key milestone in Boehringer Ingelheim’s commitment to modernizing pharmacovigilance through scalable, AI-based automation. By optimizing case recording and minimizing manual tasks, the solution empowers safety teams to concentrate on higher-value activities, such as medical review and benefit-risk analysis.
“Our mission in pharmacovigilance is to ensure patient safety while continuously improving efficiency and quality,” stated a senior official at Boehringer Ingelheim. “By leveraging LifeSphere NavaX, we are unlocking the potential of AI and automation to transform how our teams process cases – faster, more flexibly, and with greater accuracy. This partnership supports our long-term vision to create a sustainable safety organization.”
According to a company release, Steve Nuckols, Head of Customer Service at ArisGlobal, emphasized the significance of this implementation. “This go-live is more than a technological milestone; it’s a compelling example of how leading pharmaceutical companies can utilize GenAI to build scalable, intelligent pharmacovigilance ecosystems,” he said. “Boehringer Ingelheim is a valued innovation partner, and we are proud to support their vision with LifeSphere NavaX now and in the future.”
NavaX serves as the cognitive computing engine powering all AI products within the LifeSphere® Unify platform. Its advanced automation capabilities enable organizations to meet evolving regulatory requirements, enhance compliance, and increase operational agility. The implementation at Boehringer Ingelheim reflects a growing trend among pharmaceutical leaders who are adopting NavaX to modernize safety processes through scalable, AI-driven automation.
ArisGlobal, an AI-based technology company and the creator of LifeSphere®, is dedicated to transforming how life science companies develop groundbreaking innovations and bring new products to market. Headquartered in the United States, ArisGlobal maintains regional offices in Europe, India, Japan, and China. Further updates can be found on the company’s LinkedIn page: www.arisglobal.com.
Logo – https://mma.prnewswire.com/media/1510670/ArisGlobal_Logo.jpg
